Evaluation of the Risk of Clinical Deterioration among Inpatients with COVID-19

Table 4

Medications taken before admission and chest CT severity at admission compared to the patient’s evolution to the ICU.

	Hosp_Intern (n = 59)	ICU (n = 15)	value
Used medications
Ceftriaxone	17 (23.0)	7 (9.5)	0.223
Hydroxychloroquine	34 (45.9)	6 (8.1)	0.221
Azithromycin	52 (70.3)	14 (18.9)	0.563
Ivermectin	27 (36.5)	11 (14.9)	0.056
Enoxaparin	25 (33.8)	8 (10.8)	0.446
Chlorpromazin	16 (21.6)	6 (8.1)	0.355
Chest CT findings
Bilateral ground-glass opacity	43 (58.9)	15 (20.5)	0.030
Unilateral ground-glass opacity	8 (11.0)	0 (0.0)
Chest CT gravity
Involvement 25–50%	12 (16.4)	4 (5.5)	0.027
Involvement > 50%	1 (1.4)	3 (4.1)
Pleural effusion	1 (1.4)	2 (2.7)
Chest CT nongravity
Clear	6 (8.2)	0 (0.0)
Involvement < 25%	38 (52.1)	6 (8.2)
Nodules	14 (19.2)	0 (0.0)
Length of stay (days)	6.2 (±SD: 2.7)	10.7 (±SD: 8.7)	<0.001

n (%); values were calculated by the Mann–Whitney U test, χ2 test, or Fisher’s exact test.